Publications by authors named "Seth Warner"
Article Synopsis
- Researchers created a non-human primate model of septic shock to better study the disease and test new treatments under conditions similar to modern intensive care.
- The study analyzed how different doses of a bacteria impacted the animals, noting significant effects on heart rate, blood pressure, and organ function.
- The model showed key immunological and pathological responses similar to human sepsis, revealing potential for its use in understanding disease mechanisms and developing effective therapies.
Modulating SYK has been demonstrated to have impacts on pathogenic neutrophil responses in COVID-19. During sepsis, neutrophils are vital in early bacterial clearance but also contribute to the dysregulated immune response and organ injury when hyperactivated. Here, we evaluated the impact of R406, the active metabolite of fostamatinib, on neutrophils stimulated by LPS.
View Article and Find Full Text PDFBackground: Existing models of Ebola virus infection have not fully characterized the pathophysiology of shock in connection with daily virologic, clinical, and immunologic parameters. We implemented a nonhuman primate critical care model to investigate these associations.
Methods: Two rhesus macaques received a target dose of 1000 plaque-forming units of Ebola virus intramuscularly with supportive care initiated on day 3.
Spleen tyrosine kinase (SYK) is a previously unidentified therapeutic target that inhibits neutrophil and macrophage activation in coronavirus disease 2019 (COVID-19). Fostamatinib, a SYK inhibitor, was studied in a phase 2 placebo-controlled randomized clinical trial and was associated with improvements in many secondary end points related to efficacy. Here, we used a multiomic approach to evaluate cellular and soluble immune mediator responses of patients enrolled in this trial.
View Article and Find Full Text PDFUnderstanding early innate immune responses to coronavirus disease 2019 (COVID-19) is crucial to developing targeted therapies to mitigate disease severity. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection elicits interferon expression leading to transcription of IFN-stimulated genes (ISGs) to control viral replication and spread. SARS-CoV-2 infection also elicits NF-κB signaling which regulates inflammatory cytokine expression contributing to viral control and likely disease severity.
View Article and Find Full Text PDFObjective: COVID-19 and associated measures to control the spread of the COVID-19 has significantly impacted clinical research. This study aimed to determine the impact COVID-19 has had on psychiatric clinical trials and to assess whether certain trial areas or trial types were differentially affected.
Methods: We used information from ClinicalTrials.
Article Synopsis
- A study tested the drug fostamatinib on hospitalized adults with severe COVID-19 to see if it could improve their immune response and overall health outcomes.
- In the trial, 59 patients were randomized to either receive fostamatinib or a placebo while receiving standard care, with serious adverse events monitored over 29 days.
- Results showed that fostamatinib led to fewer serious side effects and improved clinical outcomes, especially in patients with severe cases, suggesting it could be beneficial and should be tested further.
Objective: To assess the potential for a new channel for effective vaccine health communication in the United States: the nation's health education teachers.
Methods: Content analysis of current curricular standards governing health education in the fifty states and the District of Columbia, and a 2019 nationally representative survey of middle and high school health education teachers in the United States.
Results: Only 12 states require any discussion of vaccines or immunization, and none provide detailed guidance to teachers on critical knowledge that might help young adults make wise immunization decisions.